Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > Takeda’s £46 Billion Shire Buyout
Takeda’s £46 Billion Shire Buyout
-
Takeda Completes £46 Billion Shire Acquisition
January 8, 2019
-
After Thumbs-Up Given to Shire Buy, Weber’s Leadership Will Now Be Put to Test
December 12, 2018
-
Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold
December 6, 2018
-
Takeda Shareholders OK £46 Billion Shire Takeover
December 5, 2018
-
Takeda Family Member Comes Forward for Final Appeal to Veto Shire Deal, but Admits Uphill Battle
December 4, 2018
-
Takeda Inks US$3.7 Billion Loan Accord with JBIC
December 4, 2018
-
Dissident Shareholder Group Hails Ex-Takeda Chief’s Opposition to Shire Deal
November 29, 2018
-
Dissident Takeda Shareholders Making Final Pitch to Thwart Shire Buyout
November 26, 2018
-
Takeda Gets European OK for Shire Deal with Strings Attached
November 21, 2018
-
Takeda to Issue US$5.5 Billion in Bonds for Shire Acquisition
November 21, 2018
-
Takeda to Procure €7.5 Billion in Bonds for Shire Acquisition
November 19, 2018
-
Big Takeda Could Debut as Early as January 8, De-facto Vote on Shire Deal Set for Dec. 5
November 13, 2018
-
Takeda Unveils Estimated Net Debt, Goodwill Post Shire Integration
November 2, 2018
-
Takeda Unveils Post-Acquisition Executive Team, 2 of 20 Members from Shire
November 1, 2018
-
Takeda Mulls Sale of Shire GI Pipeline to Clinch European Clearance
October 29, 2018
-
Takeda Earns Japan Clearance for Shire Acquisition
October 19, 2018
-
Takeda Alumni Shareholders Send Open Letter Questioning Shire Buyout
October 9, 2018
-
Takeda Gets China OK for Shire Takeover
September 18, 2018
-
Takeda Integration Team Prepping for Shire Takeover: Weber
August 1, 2018
-
Takeda Clinches Key US Clearance for Shire Takeover
July 10, 2018
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…